Dr Ovidiu Novac
Senior Scientist, CN Bio Innovations
Got a Question for Dr Ovidiu Novac?
Get in touch using the contact form linked here and we’ll get back to you shortly.
Published Content
Total: 2
Webinar
The Dash for NASH: How To Succeed in NASH Therapeutic Development
On-Demand
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders that affects 25% of our global population. 20% of those with NAFLD develop non-alcoholic steatohepatitis (NASH), which can result in cirrhosis and liver cancer.
Despite continued research and development efforts, not one NASH therapeutic agent has made it to market yet. Traditional preclinical tests have repeatedly failed to predict human drug efficacy as they inadequately recreate the complexity and multifaceted nature of this human disease. As a result, NASH is poised to become a global health and economic burden.
Is it time to increase your chances of clinical success with a new human-relevant approach to drug discovery and development?
Despite continued research and development efforts, not one NASH therapeutic agent has made it to market yet. Traditional preclinical tests have repeatedly failed to predict human drug efficacy as they inadequately recreate the complexity and multifaceted nature of this human disease. As a result, NASH is poised to become a global health and economic burden.
Is it time to increase your chances of clinical success with a new human-relevant approach to drug discovery and development?
Webinar
Human Liver Microphysiological System for Studying Acute and Chronic Drug-Induced Liver Toxicity
On-Demand
With safety concerns being the major cause for failures in Phase 1/2 clinical trials, it’s essential to develop more predictive models within preclinical drug discovery to improve data translatability.
Advertisement
